TSPO and Duchenne muscular dystrophy: The strengths of our proposed protocol include: (1) the utility of non-invasive inflammation imaging using second generation TSPO radioligand [18F]FEPPA, (2) the use of a high-resolution (1.4–1.5 mm) small animal PET scanner capable of multi-organ/whole-body image data acquisition, and (3) the showcase of tissue-specific dosimetry and molecular colocalization capabilities via biodistribution and autoradiography respectively in a murine model of DMD—allowing for the additional in vitro histopathological validation of our in vivo imaging studies.